Cellosaurus logo
expasy logo

Cellosaurus RPCI-WM1/IR (CVCL_VJ33)

[Text version]
Cell line name RPCI-WM1/IR
Accession CVCL_VJ33
Resource Identification Initiative To cite this cell line use: RPCI-WM1/IR (RRID:CVCL_VJ33)
Comments Selected for resistance to: ChEBI; CHEBI_76612; Ibrutinib (Imbruvica).
Derived from site: In situ; Lymph node; UBERON=UBERON_0000029.
Sequence variations
  • Mutation; HGNC; HGNC:7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (from parent cell line).
Disease Waldenstrom macroglobulinemia (NCIt: C80307)
Waldenstrom macroglobulinemia (ORDO: Orphanet_33226)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_M087 (RPCI-WM1)
Sex of cell Female
Age at sampling 48Y
Category Cancer cell line
Publications

PubMed=28548645; DOI=10.1038/bcj.2017.40; PMCID=PMC5518884
Paulus A., Akhtar S., Yousaf H.M., Manna A., Paulus S.M., Bashir Y., Caulfield T.R., Blake M.K.K., Chitta K.S., Wang X., Asmann Y., Hudec R., Springer W., Ailawadhi S., Chanan-Khan A.A.
Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment.
Blood Cancer J. 7:e565.1-e565.11(2017)

Cross-references
Cell line databases/resources cancercelllines; CVCL_VJ33
Encyclopedic resources Wikidata; Q98129163
Polymorphism and mutation databases Cosmic; 2645647
Entry history
Entry creation07-Sep-2018
Last entry update19-Dec-2024
Version number11